The 8q24 region hosts miRNAs altered in biospecimens of colorectal and bladder cancer patients.
8q24 genomic region
bladder cancer
colorectal cancer
microRNAs
stool
urine
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
14
09
2022
received:
22
07
2022
accepted:
10
10
2022
pubmed:
12
11
2022
medline:
24
3
2023
entrez:
11
11
2022
Statut:
ppublish
Résumé
The 8q24 locus is enriched in cancer-associated polymorphisms and, despite containing relatively few protein-coding genes, it hosts the MYC oncogene and other genetic elements connected to tumorigenesis, including microRNAs (miRNAs). Research on miRNAs may provide insights into the transcriptomic regulation of this multiple cancer-associated region. We profiled all miRNAs located in the 8q24 region in 120 colorectal cancer (CRC) patients and 80 controls. miRNA profiling was performed on cancer/non-malignant adjacent mucosa, stool, and plasma extracellular vesicles (EVs), and the results validated with The Cancer Genome Atlas (TCGA) data. To verify if the 8q24-annotated miRNAs altered in CRC were dysregulated in other cancers and biofluids, we evaluated their levels in bladder cancer (BC) cases from the TCGA dataset and in urine and plasma EVs from a set of BC cases and healthy controls. Among the detected mature miRNAs in the region, 12 were altered between CRC and adjacent mucosa (adj. p < 0.05). Five and four miRNAs were confirmed as dysregulated in the CRC and BC TCGA dataset, respectively. A co-expression analysis of tumor/adjacent tissue data from the CRC group revealed a correlation between the dysregulated miRNAs and CRC-related genes (PVT1 and MYC) annotated in 8q24 region. miR-30d-5p and miR-151a-3p, altered in CRC tissue, were also dysregulated in stool of CRC patients and urine of BC cases, respectively. Functional enrichment of dysregulated miRNA target genes highlighted terms related to TP53-mediated cell cycle control. Altered expression of 8q24-annotated miRNAs may be relevant for the initiation and/or progression of cancer.
Sections du résumé
BACKGROUND
The 8q24 locus is enriched in cancer-associated polymorphisms and, despite containing relatively few protein-coding genes, it hosts the MYC oncogene and other genetic elements connected to tumorigenesis, including microRNAs (miRNAs). Research on miRNAs may provide insights into the transcriptomic regulation of this multiple cancer-associated region.
MATERIAL AND METHODS
We profiled all miRNAs located in the 8q24 region in 120 colorectal cancer (CRC) patients and 80 controls. miRNA profiling was performed on cancer/non-malignant adjacent mucosa, stool, and plasma extracellular vesicles (EVs), and the results validated with The Cancer Genome Atlas (TCGA) data. To verify if the 8q24-annotated miRNAs altered in CRC were dysregulated in other cancers and biofluids, we evaluated their levels in bladder cancer (BC) cases from the TCGA dataset and in urine and plasma EVs from a set of BC cases and healthy controls.
RESULTS
Among the detected mature miRNAs in the region, 12 were altered between CRC and adjacent mucosa (adj. p < 0.05). Five and four miRNAs were confirmed as dysregulated in the CRC and BC TCGA dataset, respectively. A co-expression analysis of tumor/adjacent tissue data from the CRC group revealed a correlation between the dysregulated miRNAs and CRC-related genes (PVT1 and MYC) annotated in 8q24 region. miR-30d-5p and miR-151a-3p, altered in CRC tissue, were also dysregulated in stool of CRC patients and urine of BC cases, respectively. Functional enrichment of dysregulated miRNA target genes highlighted terms related to TP53-mediated cell cycle control.
CONCLUSIONS
Altered expression of 8q24-annotated miRNAs may be relevant for the initiation and/or progression of cancer.
Identifiants
pubmed: 36366788
doi: 10.1002/cam4.5375
pmc: PMC10028171
doi:
Substances chimiques
MicroRNAs
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5859-5873Subventions
Organisme : Medical Research Council
ID : MR/S019669/1
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancers (Basel). 2020 Jun 09;12(6):
pubmed: 32527011
Hum Mol Genet. 2008 Oct 15;17(R2):R109-15
pubmed: 18852198
Mol Carcinog. 2016 Nov;55(11):1833-1842
pubmed: 27439749
Genome Res. 2010 Sep;20(9):1191-7
pubmed: 20627891
Genes Cancer. 2010 Jun;1(6):555-9
pubmed: 21779458
FEBS Open Bio. 2021 Feb;11(2):529-540
pubmed: 33145996
Onco Targets Ther. 2020 Jan 14;13:389-399
pubmed: 32021284
BMC Bioinformatics. 2018 Dec 31;19(Suppl 19):514
pubmed: 30598108
PLoS One. 2012;7(10):e47454
pubmed: 23077621
J BUON. 2018 Jan-Feb;23(1):48-54
pubmed: 29552759
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
EMBO J. 2017 Oct 2;36(19):2829-2843
pubmed: 28814448
Saudi J Biol Sci. 2022 Jun;29(6):103255
pubmed: 35495735
Gastroenterology. 2020 Dec;159(6):2146-2162.e33
pubmed: 32805281
Cancer Med. 2023 Mar;12(5):5859-5873
pubmed: 36366788
Ann Surg Oncol. 2018 Jun;25(6):1454-1455
pubmed: 29616422
Genome Biol. 2014;15(12):550
pubmed: 25516281
Oncogene. 2018 Feb 8;37(6):697-709
pubmed: 29059164
Mol Med Rep. 2020 Jan;21(1):360-370
pubmed: 31939622
Clin Breast Cancer. 2020 Apr;20(2):e113-e126
pubmed: 31899158
Sci Rep. 2021 Oct 19;11(1):20645
pubmed: 34667192
Oncotarget. 2017 Dec 14;9(3):3097-3111
pubmed: 29423032
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Oncogene. 2019 Aug;38(33):6109-6122
pubmed: 31308487
Oncogene. 2010 Apr 22;29(16):2393-403
pubmed: 20154719
Front Genet. 2012 Apr 30;3:69
pubmed: 22558003
J Extracell Vesicles. 2019 Jan 29;8(1):1567219
pubmed: 30728923
Int J Mol Sci. 2019 Nov 16;20(22):
pubmed: 31744051
mSystems. 2019 Sep 17;4(5):
pubmed: 31530647
Cell Physiol Biochem. 2018;50(5):1964-1987
pubmed: 30396166
Int J Cancer. 2013 Oct 15;133(8):2004-9
pubmed: 23553206
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Oncogene. 2015 Jan 8;34(2):199-208
pubmed: 24362523
Trends Cancer. 2018 Dec;4(12):810-822
pubmed: 30470303
Semin Cancer Biol. 2006 Aug;16(4):253-64
pubmed: 16904903
PLoS One. 2015 Dec 17;10(12):e0144708
pubmed: 26678268
Neoplasma. 2022 May;69(3):583-593
pubmed: 35225646
Mol Cancer Res. 2008 Feb;6(2):212-21
pubmed: 18314482
Ann Oncol. 2017 Aug 01;28(8):1882-1888
pubmed: 28838211
J Orthop Surg Res. 2022 Feb 5;17(1):74
pubmed: 35123530
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Pharmaceuticals (Basel). 2021 Aug 28;14(9):
pubmed: 34577564
Oncotarget. 2018 Apr 17;9(29):20658-20669
pubmed: 29755679
Hum Mol Genet. 2022 Jun 4;31(11):1806-1820
pubmed: 34919704
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12
pubmed: 18077431
Cancer Biother Radiopharm. 2018 Jun;33(5):203-211
pubmed: 29916747
Genes (Basel). 2020 Mar 15;11(3):
pubmed: 32183428